It has demonstrated therapeutic activity in MERTK and FLT3-dependent cell line xenograft models and PDX models, showing promising therapeutic potential.163 It also has activity against primary AML patient samples while not affecting normal hematopoietic cells. This evidence concerns the gene FLT3 and acute myeloid leukemia.